July 07, 2010 09:09 ET

New Report Details Rapid Innovation and Growth in Biopharma

ROCKVILLE, MD--(Marketwire - July 7, 2010) - has announced the addition of Fuji-Keizai USA, Inc.'s new report "Global Market: Biopharmaceuticals Market Trends & Competition," to their collection of Biopharmaceuticals market reports. For more information, visit

Today's pharmaceutical industry is shifting toward biopharmaceuticals at a drastic speed. In 2009, sales of biopharmaceutical drugs accounted for 13% of the total sales of pharmaceuticals. And today, biopharmaceuticals account for 25% of all pharmaceuticals in the development pipeline. We expect that biopharmaceuticals will maintain double digit growth in the years to come, and form a rapidly growing market.

Eying this dramatically expanding market, companies are expanding biopharmaceutical discovery and development, and becoming active in M&A activities including involvement in bio-ventures. As a result, competition is becoming increasingly fierce.

In this study, the current state and future trends of biopharmaceutical drugs in the global market are described and reported on, including:

1. Market Overview
2. Worldwide Biopharmaceutical Drug Market Trends, 2009-2013
3. US Biopharmaceutical Drug Market Trends

US Sales of Biopharmaceutical Drugs by Disease Category, 2009-2013
New Drug Market Entries by Disease Category, 2009-2013
Manufacturers' Share by Disease Category

4. Worldwide Innovative Biopharmaceutical Dug Development by Disease Category

New Drug Pipelines by Disease Category
New Players to Enter the Market by Disease Category
Beyond the Pipeline: Hot Categories and Players' Product Development Strategy

5. Worldwide Biopharmaceutical Drug Strategies by Major Company

Major Alliances, M&A and IP
Worldwide Biopharmaceutical Drug Strategies by Major Company
Worldwide Biopharmaceutical Drug R&D by Major Company
Patents, Business Development & Challenges for Worldwide Biopharmaceutical Drug by Major Company

6. Important Findings and Suggestions for Business Opportunities

For more information, visit

Contact Information